Overview Treatment-Resistant Bipolar Disorder. Management of Bipolar Disorder When First-Line Interventions Fail Practical Tips
|
|
- Frederica Garrett
- 6 years ago
- Views:
Transcription
1 Overview Management of Bipolar Disorder When Interventions Fail Practical Tips Terence A. Ketter, MD Professor of Psychiatry and Behavioral Sciences Stanford University School of Medicine Stanford, California Candidates for beyond first-line interventions Inadequate efficacy, safety/tolerability, feasibility Urgent efficacy need Clinical circumstances important Accurate diagnoses (primary secondary) Illness phase (acute mania/depression, maintenance) Illness characteristics (rapid cycling, comorbidities, med Hx) Efficacy need (urgent non-urgent care) Primary priority (efficacy tolerability) Beyond first-line intervention options include Switching (no efficacy and/or inadequate tolerability) Augmenting (partial efficacy and adequate tolerability) Adjunctive psychosocial treatments Publishing, Inc.; 21. Established Clinical Correlates of Bipolar Depression Commonly antidepressant-resistant/exacerbated Antidepressant-resistance commonly already demonstrated Mixed Episodes (DSM-IV-TR) Commonly lithium-resistant Commonly antidepressant-resistant/exacerbated Rapid Cycling Commonly mood stabilizer-resistant Commonly antidepressant-resistant/exacerbated Comorbid Disorders Alcohol/substance use and anxiety disorders most common Not otherwise specified Subtype Misdiagnosis (eg, personality disorder, BD-I, BD-II) Missed diagnosis (eg, personality disorder, BD-I, BD-II) Adjunctive psychotherapy commonly underutilized, can be crucial BD-I = bipolar I disorder; BD-II = bipolar II disorder. Goldberg JF. J Clin Psychiatry. 28;9(3):9-9. Bipolar Disorders Symptoms are Chronic and Predominantly Depressive 1 BD-I Patients followed 12.8 years 8.9% 31.9%.9% 2.7% Percent of Weeks Asymptomatic Depressed Elevated 8 BD-II Patients followed 13. years.3% 1.3% 2.3%.1% Cycling / mixed Dep:Elevated/Cycling/mixed = 2.2:1 Dep:Elevated/Cycling/mixed = 1:1 Judd LL, et al. Arch Gen Psychiatry. 22;9():3-37. Judd LL, et al. Arch Gen Psychiatry. 23;(3): Additional Clinical Correlates of Early (Childhood > Adolescent) Onset Confounds/confounded by multiple unfavorable illness characteristics Episode Accumulation (eg, 1 episodes) Kindling Hypothesis (episodes beget illness/episode-related worsening) Episodes: spontaneous/frequent/severe, reactive/rx responsive Confounded by early onset, long illness duration, and aging Additional Comorbid Disorders Personality and eating disorders Less common than alcohol/substance use and anxiety disorders Major Depressive Episode with mixed features (DSM-) AKA Mixed Depression Limited data suggest antidepressants problematic Long Illness Duration (eg, 1 years) Confounded by early onset, episode accumulation, and aging Unfavorable Bipolar II Subtype Chronic, treatment-resistant, depressive illness (ie, BD clinic selection bias) Rather than episodic, treatment-responsive, psychotic illness (ie, not BD-I) Publishing, Inc.; 21. Unfavorable Illness Correlates of Early-Onset Bipolar Disorder Unfavorable Illness Characteristic Prevalence: Childhood- > Adolescent- > Adult-Onset Bipolar Disorder P <., P <.1, P <.1, P <.1 adult-onset. Holtzman JN, et al. J Affect Disord. 21;179:11-12.
2 Median Illness Course in 82 Patients with Severe Acute Mania FDA-Approved Agents for Bipolar Disorder Acute Depression Longer Term Moderate Mild Age Mild Moderate Severe First Symptoms First Treatment First Hospitalization. hypo/manias (8 weeks duration); 8. depressions (11 weeks duration); hospitalizations; 1. episodes/year; 3 episodes year before NIMH NIMH = National Institute of Mental Health (Intramural Program). Post RM, et al. Am J Psychiatry. 1988;1(7):8-88. NIMH Admission 197 Lithium 1973 Chlorpromazine 199 Divalproex, ER (2) 2 Olanzapine 23 Risperidone 2, XR (28) 2 Ziprasidone 2 Aripiprazole 2 Carbamazepine ERC 29 Asenapine 21 Cariprazine 23 Olanzapine+fluoxetine combination 2, XR (28) 213 Lurasidone Unmet Need 197 Lithium 23 Lamotrigine 2 Olanzapine 2 Aripiprazole 28, XR (adjunct) 29 Risperidone LAI 29 Ziprasidone (adjunct) Unmet Need Adjunctive and monotherapy. ER, XR, ERC = extended release oral; LAI = long-acting injectable. Publishing, Inc.; 21. Tolerability- First Approach Psychotropic Medication Adverse Effect Schematic Adverse effect risk over placebo (NNH) Medication Class Acute Mania FDA-Approved Agents for Bipolar Disorder Acute Depression Longer Term More Adverse Effects (Go here if necessary) Medium ( 1%) (NNH = 1 2) Low (< %) (NNH > 2) Fewer Adverse Effects (Start here if appropriate) Ketter TA, et al. J Affect Disord. 21;19 Suppl 1:S2-S33. High (> 1%) (NNH < 1) CLZ OLZ RSP, QTP ZIP, ARI, ASN, ILO LUR, BREX, CARI Li, VPA, CBZ LTG FLX, SERT, PAR, BUP, MIRT, (ES)CIT, DLX, (DES)VEN, VTX, VIL, L-MILNA Older Newer SGAs Older Mood Stabilizers Newer Antidepressants 197 Lithium 1973 Chlorpromazine 199 Divalproex, ER (2) 2 Olanzapine 23 Risperidone 2, XR (28) 2 Ziprasidone 2 Aripiprazole 2 Carbamazepine ERC 29 Asenapine 21 Cariprazine 23 Olanzapine+fluoxetine combination 2, XR (28) 213 Lurasidone Unmet Need 197 Lithium 23 Lamotrigine 2 Olanzapine 2 Aripiprazole 28, XR (adjunct) 29 Risperidone LAI 29 Ziprasidone (adjunct) Unmet Need Publishing, Inc.; 21. Multiphase Treatment Strategy Acute Continuation Maintenance Duration 3 8 weeks 2 months Indefinite Symptoms Syndromal Subsyndromal / Absent Absent / Subsyndromal Episode Goals Overt Response Remission (Ideally) ± Overt / Covert (Partially / Fully Suppressed) Recovery Relapse Prevention Improved Function Absent / ± Overt Recurrence Relapse Prevention Full Function Priority Efficacy Efficacy Tolerability Balance Tolerability Medications Psychosocial Increase, Add Support / Structure Education Involve Family Continue, ± Decrease, ± Increase Adherence Cognitive, Behavioral, Family Institute Monitoring Optimize Address Prodromes Adherence Optimize Adaptation Anticipate Prodromes Publishing, Inc.; 21. Adapted from Sachs GS. J Clin Psychopharmacol. 199;1(2 Suppl 1):32S-7S. Sachs GS. J Clin Psychiatry. 23; Suppl 8:3-. Keller MB. J Clin Psychiatry. 2; Suppl 1:1-1. Swann AC. J Clin Psychiatry. 2; Suppl 1:7-12. Overview of Bipolar Disorder Registration Studies Numbers Needed to Treat for Response and Relapse Prevention, Rates Patients (%) NNT Acute Mania Response Monotherapy Combination Monotherapy 2% 21% 31% (non-urgent) Li/VPA/ PBO CBZ/SGA 9% 18% 1% (urgent) 82 SGA + Li/VPA Li/VPA Acute Depression Response Maintenance Relapse Publishing, Inc.; 21. FDA-approved bipolar disorder treatments increase good outcomes by 18% 2%. Monotherapy/Combination /Monotherapy % 2% 3% (urgent) OFC/QTP/ PBO/ LUR Li/VPA Monotherapy 23% 3% Li/LTG/ SGA 7% (tolerability) PBO Combination Monotherapy 2% % 19% (efficacy) 91 9 = N QTP/ZIP/ARI Li/VPA + Li/VPA
3 Treatments Bipolar Treatments Common usage definitions Preferred, standard, or first choice (Merriam-Webster Dictionary) First chosen for particular illness (Cambridge Dictionary) First given for disease (National Cancer Institute Dictionary of Cancer Terms) Top priority for most patients in such clinical circumstances Operational definition Optimal efficacy/tolerability/feasibility for patients in such clinical circumstances Feasibility factors Accessibility (including cost); Acceptability (including adherence) Ease of use (including drug interactions and dietary restrictions) Efficacy/tolerability evidence levels for individuals Observational (Historical patient ± first-degree relative(s)) In that particular patient in similar clinical circumstances ± In that patient s first-degree-relative(s) in similar clinical circumstances (?) Evidence-based (RCTs) In similar patient population in similar clinical circumstances RCT = randomized controlled trial. Publishing, Inc.; 21. Acute hypo/mania Lithium/divalproex monotherapy Efficacy > tolerability priority (urgent care, inpatient) Approved lithium/divalproex + newer SGA combinations Acute bipolar depression Lamotrigine, ADs (RCTs suggest particularly limited AD efficacy) Efficacy > tolerability priority (urgent care, inpatient) Lurasidone (monotherapy or added to lithium/divalproex) Bipolar maintenance Prior effective acute treatment (with dose adjustment(s) for tolerability) Lamotrigine (esp. depression prevention)/lithium (esp. elevation prevention) AD = antidepressant; SGA = second-generation antipsychotic. Publishing, Inc.; 21. NOT Bipolar Treatments Acute hypo/mania Carbamazepine monotherapy (selected second-line) Olanzapine, risperidone, quetiapine monotherapy (third-line) Lithium/divalproex + SGA combinations (third-line) Efficacy > tolerability priority (urgent care, inpatient) Clozapine (fourth-line) Acute bipolar depression Nutriceuticals (fourth-line; limited efficacy data) Efficacy > tolerability priority (urgent care, inpatient) Olanzapine + fluoxetine combination (third-line) Bipolar maintenance SGAs (second- and third-line) Acute Hypo/mania Treatment Publishing, Inc.; 21. Non-urgent Care (Outpatient) Acute Hypo/mania Treatments Monotherapies (and selected combination therapies) First-line Lithium/divalproex (not carbamazepine/lamotrigine) monotherapy ie, Li/DVPX monotherapy Second-line Carbamazepine monotherapy (not lamotrigine) Newer approved SGA monotherapy ie, ARI/ZIP/ASN/CARI monotherapy Third-line Older approved SGA monotherapy ie, OLZ/QTP/RSP monotherapy Urgent care (inpatient) acute mania combination treatments (next slide) Fourth-line FGA monotherapy eg, haloperidol Lithium + antimanic anticonvulsant ie, Li + DVPX; or Li + CBZ; (but not Li + LTG) FGA = first-generation antipsychotic. Publishing, Inc.; 21. Urgent Care (Inpatient) Acute Mania Treatments Combination therapies First-line Lithium/divalproex + newer approved SGA eg, Li/DVPX + ARI/ASN Second-line Lithium/divalproex + older SGA ± newer SGA eg, Li/DVPX + OLZ/QTP/RSP ± ARI/ASN Third-line Li/DVPX + FGA ± older SGA ± newer SGA eg, Li/DVPX + haloperidol ± OLZ/QTP/RSP ± ARI/ASN Fourth-line Lithium/divalproex + clozapine ± FGA ± older SGA ± newer SGA eg, Li/DVPX + clozapine ± haloperidol ± OLZ/QTP/RSP ± ARI/ASN Electroconvulsive therapy (commonly + SGA/FGA) Publishing, Inc.; 21.
4 Overview of 2 Acute Mania Registration Studies Numbers Needed to Treat for Response, Rates Responders (%) ( % Mania Rating Decrease) 2 Monotherapy Combination Studies Therapy Studies NNT Monotherapy 1.% 2.3% Combination Monotherapy 9.% 18.1% 1.3% % 2 1 (non-urgent) (urgent) = N P <.1. Li/DVPX/CBZ/SGA PBO SGA + Li/DVPX Li/DVPX Publishing, Inc.; 21. Adjunctive SGA Therapy Monotherapy Increases Response Rate 18%. Acute Bipolar Depression Treatment Non-urgent Care (Outpatient) Acute Bipolar Depression Treatments Monotherapies (and selected combination therapies) First-line Lamotrigine monotherapy AD ± lithium/divalproex (AD monotherapy in certain BD-II, but not BD-I) RCTs suggest particularly limited antidepressant efficacy Second-line Lithium ± lamotrigine Adjunctive psychotherapy (CBT, FFT, IPSRT) Urgent care (inpatient) acute bipolar depression monotherapies (next slide) eg, LUR/QTP monotherapy Third-line Divalproex/carbamazepine Urgent care (inpatient) acute bipolar depression combination therapies (next slide) eg, SGA + MS (including QTP + LTG), SGA + AD Lithium + antimanic anticonvulsant eg, Li + DVPX, Li + CBZ Fourth-line Novel agents/adjunctive therapies eg, thyroid, pramipexole, topiramate, nutriceuticals, sleep dep, light Rx, CBZ/DVPX ± Li MS = mood stabilizer; CBT = cognitive-behavioral therapy; FFT = functional family therapy; IPSRT = interpersonal and social rhythm therapy. Publishing, Inc.; 21. Urgent Care (Inpatient) Acute Bipolar Depression Treatments Monotherapies and selected combination therapies First-line Newer approved SGA ie, LUR (monotherapy or added to Li/DVPX) Second-line Older approved SGA monotherapy ie, QTP monotherapy Adjunctive psychotherapy (CBT, FFT, IPSRT) Third-line Older approved SGA + antidepressant combination ie, OLZ + FLX Novel adjunctive therapies ie, armodafinil, modafinil, (QTP + LTG) Fourth-line Adjunctive neuromodulation eg, ECT, TMS, VNS Other novel adjunctive therapies eg, thyroid, pramipexole, topiramate, nutriceuticals, sleep dep, light Rx, CBZ/DVPX ± Li ECT = electroconvulsive therapy; TMS = transcranial magnetic stimulation therapy; VNS = vagus nerve stimulation. Publishing, Inc.; 21. Initial Treatment for Bipolar Disorder Patients in the United States in Initial Prescription Rate % N = 77 2% (17% AC, 8% Li) Antidepressants Mood Stabilizers AC = anticonvulsants; Li = lithium. Baldessarini RJ, et al. Psychiatr Serv. 27;8(1): % Sedatives 11% Antipsychotics Tolerability-Prioritized Unapproved Bipolar Depression Rx Benefits and Harms NNT and NNH, Response and Adverse Effect Rates Lamotrigine Benefit (NNT) Harm (NNH) MADRS Response Somnolence NNT / NNH Lamotrigine Lamotrigine.% 8.% 38.1% Benefit / Harm (%) 3 Antidepressants Benefit (NNT) Harm (NNH) Response/Remission Mood Switch Antidepressant 1.7% 38.2% %.% 9.%.8% 7.7% 7.2% 1 3 = N 1 8 = N LTG PBO LTG PBO AD PBO AD PBO Geddes JR, et al. Br J Calabrese JR et al. Bipolar Disord. Sidor MM, et al. J Clin Psychiatry. Psychiatry. 29;19(1):-9. 28;1(2): Geddes JR et al. 211;72(2):1-17. P <.1 PBO. Br J Psychiatry. 29;19(1):-9. MADRS = Montgomery-Åsberg Depression Rating Scale. Lamotrigine and antidepressants more than twice as likely to yield benefit as harm compared to PBO. 3.% Antidepressant
5 Antidepressant-Induced Mania More Common in Bipolar II Compared to Unipolar Depression Switching to Mania (%) Meta-Analysis from Clinical Trials Unipolar Depression Bipolar II Depression 11.2% 3.7%.2% 2.%.7%.2% ,2 = N = N Statistical Significance: TCA = SSRI > PBO TCA > SSRI = PBO SSRI = selective serotonin reuptake inhibitor (fluoxetine, fluvoxamine, paroxetine, or sertraline); TCA = tricyclic antidepressant. Switch Risk: Bipolar II > Unipolar; TCA SSRI PBO. Peet M. Br J Psychiatry. 199;1():9-. Increased Switching with Adjunctive Venlafaxine Compared to Bupropion and Sertraline in Bipolar Depression Patients (%) % 1 BUP YMRS > 13 NNH 1 13 VEN BUP P =. 1% VEN Harm (NNH) Mood Switch VEN SERT 7% 8 SERT CGI-M Increase 2 1% 1 BUP VEN BUP P <.1 29% VEN SERT 73% BD-I, 2% BD-II, 1% bipolar NOS; 8% double-blind, 1% open. YMRS = Young Mania Rating Scale; CGI-M = Clinical Global Impression Mania. Post RM, et al. Br J Psychiatry. 2;189: Adjunctive venlafaxine (compared to sertraline, bupropion) yielded more switching. VEN SERT 9% 8 YMRS > 13 or CGI-M 3 1% BUP VEN BUP P =.3 31% 1% 1 8 = N VEN 7 VEN SERT SERT Newer Efficacy-Prioritized Approved Bipolar Depression Rx Benefits and Harms NNT and NNH, Response and Adverse Effect Rates Lurasidone Monotherapy 1 Adjunctive Lurasidone 2 Benefit (NNT) Harm (NNH) Benefit (NNT) Harm (NNH) MADRS Response Akathisia MADRS Response Nausea NNT / NNH Lurasidone 1 Lurasidone 7 Lurasidone 1 Lurasidone Response / Harm (%) 3 2.% 21.8% 3.2% 7.% 1.% 2.% %.% 1 9.% 7.% 11.% = N = N LUR PBO LUR 2.% PBO LUR PBO LUR PBO P <.1, P <.1 PBO. 1 Loebel A, et al. Am J Psychiatry. 21;171(2): Loebel A, et al. Am J Psychiatry. 21;171(2): Older Efficacy-Prioritized Approved Bipolar Depression Rx Benefits and Harms NNT and NNH, Response and Adverse Effect Rates Olanzapine + Fluoxetine (OFC) Benefit (NNT) 1 Harm (NNH) 1 Benefit (NNT) 2,3 Harm (NNH) 2,3 MADRS Response 7% Weight Gain MADRS Response Sedation/Somnolence NNT / NNH Olanzapine + Fluoxetine Olanzapine + Fluoxetine 8.%.1% 18.2% 2.7%.3% 3 3.% 3.% 2 19.% 2.9% %.3%.% 82 3 = N 8 33 = N OFC PBO OFC PBO QTP PBO QTP PBO Response / Harm (%) P <.1 PBO. 1 Tohen M, et al. Arch Gen Psychiatry. 23;(11): Calabrese JR, et al. Am J Psychiatry. 2;12(7): Thase ME, et al. J Clin Psychopharmacol. 2;2():-9. NNT / NNH Benefit or Harm (%) Week Olanzapine + Fluoxetine in Pediatric Acute Bipolar I Depression NNT and NNH, Response and 7% Weight Gain Rates Benefit (NNT) CDRS-R Response Olanzapine + Fluoxetine 78.2% Mean OFC 19.% 9.2% 17 8 = N PBO Harm (NNH) 7% Weight Gain 3 Olanzapine + Fluoxetine P <.1, P <.1 PBO. 2% OFC 8% % PBO CDRS-R = Children s Depression Rating Scale Revised. Detke HC, et al. J Am Acad Child Adolesc Psychiatry. 21;(3): Comparative Evaluation of QUEtiapine plus Lamotrigine in Bipolar Depression (CEQUEL) NNTs and Remission Rates Week 12 Week 2 Benefit (NNT) Benefit (NNT) QIDS Remission ( ) QIDS Remission ( ) NNT 7 Lamotrigine + Lamotrigine % 3 31% 2 1% 23% 2 1 1% 1 13% 8 81 = N = N LTG + QTP PBO + QTP LTG + QTP PBO + QTP P <. PBO. QIDS = Quick Inventory of Depressive Symptomatology. Geddes JR, et al. Lancet Psychiatry. 21;3(1): % BD-I, 2% BD-II. QIDS Remission (%)
6 STEP-BD Bipolar Depression Studies Numbers Needed to Treat for Recovery, Rates Recovered (%) NNT -2 8 Mood Stabilizer + Antidepressant Mood Stabilizer + Bupropion - 3 (median, n = 8) Paroxetine - 3 (median, n = 93) 2 3.8% 23.% P =. 27.3% 8 Intensive Psychotherapy Brief Psychoeducation.% 12.9% 1.% Bipolar Maintenance Treatment P <. Mood Stabilizer Mood Stabilizer Intensive Brief control + Antidepressant + Psychotherapy Psychoeducation Sachs GS, et al. N Engl J Med. Miklowitz DJ, et al. Arch Gen Psychiatry. 27;3(17): ;(): Publishing, Inc.; 21. Adjunctive psychotherapy (but not adjunctive antidepressants) increased recovery rate = N Efficacy-Tolerability Balanced Bipolar Maintenance Treatments Monotherapies and selected combination therapies First-line Prior effective acute treatment(s) (with dose adjustment(s) for tolerability) Lamotrigine (esp. depression prev.)/lithium (esp. elevation prev.) monotherapy Second-line Adjunctive psychotherapy (PE, CBT, FFT, IPSRT) Divalproex monotherapy Newer approved SGA monotherapy ie, ARI monotherapy Third-line Older approved SGA monotherapy ie, OLZ/RSP LAI monotherapy Approved lithium/divalproex + SGA combo therapy ie, Li/DVPX + ARI/QTP/RSP LAI/ZIP monotherapy Fourth-line Carbamazepine monotherapy; Clozapine monotherapy/adjunctive therapy FGA monotherapy eg, haloperidol Lithium + mood-stabilizing anticonvulsant ie, Li + DVPX, Li + CBZ, Li + LTG PE = prolonged exposure. Publishing, Inc.; 21. Overview of Bipolar Monotherapy Maintenance Studies Numbers Needed to Treat for Relapse/Recurrence Prevention, Rates NNT Relapse/Recurrence (%) Lamotrigine 11% % 1% 7 Lithium 1% % LTG PBO Li Goodwin Contemporary Registration Studies 3 Olanzapine 33% 7% 8% OLZ PBO Tohen P <., P <.1, P <.1 PBO. Publishing, Inc.; 21. Aripiprazole 19% 2% 3% ARI PBO Keck Risperidone 2% 3% % 1 13 RSP PBO Quiroz 1 unapproved for maintenance monotherapy 29% 23% 2% Lithium 2% 2% 3 QTP PBO Li Weisler 11 = N Overview of Bipolar Monotherapy Maintenance Studies Numbers Needed to Treat and Harm, 7% Weight Gain Rates NNT NNH 7% Weight Gain (%) % wt gain Lamotrigine Lithium 2 7% wt gain In stabilization not reported 1.9% 3.3% 7.%.1% 7 Contemporary Registration Studies % 3 Olanzapine BUT 3% 7% wt gain In stabilization 1.1% 13.8% 2.8%.% 2.% 2.3% = N LTG PBO Li OLZ PBO ARI PBO RSP PBO QTP PBO Li Sachs Tohen Keck Quiroz 1 Weisler 11 P <., P <.1, P <.1 PBO. Publishing, Inc.; 21. Mood stabilizers antipsychotics slightly less efficacy, but better tolerability. Aripiprazole 7% wt gain In stabilization not reported 12.% 12.% Risperidone BUT 17% 7% wt gain In stabilization 11.% % 13 1.% BUT 17% 7% wt gain In stabilization unapproved for maintenance monotherapy 8.% 3 Lithium 2.8%.% Overview of Adjunctive Psychosocial Maintenance Studies Numbers Needed to Treat for Relapse/Recurrence Prevention, Rates Relapse/Recurrence (%) Contemporary Manualized Intensive Psychotherapy Studies After Sustained Recovery After Acute Episode When Euthymic / Subsyndromal NNT Psychoeducation Group Non-structured Group 2.%.7% 91.7% Family Focused Therapy Crisis Management 18.8% 3.%.3% Cognitive Therapy No Psychotherapy 31.3% 3.8% 7.% = N Psychoeducation Non-structured Family Focused Crisis Cognitive No Group Group Therapy Management Therapy Psychotherapy Colom 3 Miklowitz 3 Lam 3 P <.1, P <.1 control. Publishing, Inc.; 21. Psychotherapies had single-digit NNTs, comparable to approved pharmacotherapies.
7 Overview of Adjunctive Pharmacotherapy Bipolar Preventive Studies Numbers Needed to Treat for Relapse/Recurrence Prevention, Rates Relapse/Recurrence (%) NNT Adjunctive Adjunctive 31.1% 19.3% 7.% 8 Contemporary Registration Studies Adjunctive Risperidone Adjunctive 22.7% 23.1% 2.1.8% 9 QTP+L/V PBO+L/V RSP+TAU PBO+TAU Suppes 13 Macfadden 9 Publishing, Inc.; 21. Approved adjunctive maintenance treatments generally have single-digit NNTs. 8 Adjunctive Ziprasidone Adjunctive 32.% 12.7% 19.7% ZIP+L/V PBO+L/V Bowden 1 1 Adjunctive Aripiprazole Adjunctive p <., p <.1, p <.1. PBO. 1.% 2.% 1.9% = N ARI+L/VPBO+L/V Marcus 11 Meta-Analysis of Antidepressants in Bipolar Maintenance Benefit (NNT) Harm (NNH) Depressive Relapse Manic Relapse NNT / NNH 1 8 Antidepressant Antidepressant 3 3.% 3 1.2% 29.8% 2 2.3% 13.% % = N AD ± MS MS or PBO AD ± MS MS or PBO Patients with BD-I, BD-II, or bipolar NOS. P <., P <.1 PBO. Ghaemi SN, et al. Acta Psychiatr Scand. 28;118():37-3. Patients (%) Antidepressant Continuation Beneficial in Some (1%?) Bipolar Patients n = 1 (3% relapsed) P =. n = 3 (7% relapsed) Prospective 1-year follow-up Remission of MDE with AD added to mood stabilizer Enriched sample 1.3% (8/9) of patients responded and tolerated AD 2 months Continuation: AD > months Discontinuation: AD < months Seeking Functional Recovery (Thinking Beyond Medications and Not Settling for Sustained Clinical Remission) MDE = major depressive episode. Altshuler L, et al. Am J Psychiatry. 23;1(7): Bipolar Disorders Symptoms are Chronic and Predominantly Depressive 1 BD-I Patients followed 12.8 years 8.9% 31.9%.9% 2.7% Percent of Weeks Asymptomatic Depressed Elevated 8 BD-II Patients followed 13. years.3% 1.3% 2.3%.1% Cycling / mixed Dep:Elevated/Cycling/mixed = 2.2:1 Dep:Elevated/Cycling/mixed = 1:1 Judd LL, et al. Arch Gen Psychiatry. 22;9():3-37. Judd LL, et al. Arch Gen Psychiatry. 23;(3): Pharmacotherapy Studies Focus on Symptom Control. Illness Transition Points (The Rs, borrowed from MDD) Response Clinically significant (eg, %) improvement Partially suppressed index episode still present Remission Virtual absence of symptoms < 2 months Fully suppressed index episode still present Recovery Virtual absence of symptoms 2 months Index episode ended (ie, no episode present) Relapse Index episode returns after Response or Remission Recurrence New episode emerges after Recovery Mood Disorder Recovery Definitions Focus on Symptom Control. Publishing, Inc.; 21.; Adapted from Kupfer DJ. J Clin Psychiatry. 1991;2 Suppl 2:28-3. Frank E, et al. Arch Gen Psychiatry. 1991;8(9):81-8.
8 Recovery in Bipolar Disorder Schizophrenia: Definitions and Studies Narrower Definition Bipolar Disorder (Clinical; Shorter duration) 1 2 threshold-level depressive/mood elevation symptoms 8 weeks Schizophrenia (Clinical & Functional; Longer Duration) 2 mild symptoms mild relationship/employment deficits 2 years Fewer Psychosocial Treatment Studies Bipolar Disorder Limited studies 3 Functional Remediation Schizophrenia Multiple studies Cognitive Remediation, Social Cognition Training... 1 Perlis RH, et al. Psychiatr Serv. 27;8: Faerden A, et al. Psychopathology. 28;1(): Torrent C, et al. Am J Psychiatry. 213;17(8): Kern RS, et al. Schizophr Bull. 29;3(2): Symptomatic Much More Than Functional Recovery in Bipolar Disorder Patients (%) Months after Hospitalization 78% (33/2) Mild or No Affective Symptoms Dion GL, et al. Hosp Community Psychiatry. 1988;39(): % (9/2) Employed Full Time at Expected Level 21 Weekly 9-Minute Adjunctive Functional Remediation (but not Psychoeducation) Sessions Diminished Dysfunction in Recovered Bipolar Disorder Patients 3 Functional Impairment (Functioning Assessment Short Test) ±, Improvement from Baseline Effect Size : Bipolar I Depression 2 ±P <. PE; P <.1 TAU. Error bars are SE of mean. Completion rates FR 71.%, PE 7.%, TAU 82.% (NS). Paper-and-pencil tasks/group exercises for memory, attention, Pre-Treatment problem solving, reasoning, multitasking, and organization. Torrent C, et al. Am J Psychiatry. 213;17(8): Post-Treatment Functional Remediation (n = 77) Psychoeducation (N = 82) (n = 82) Treatment-As-Usual (N = 8) (n = 8) : Background Demographics - 21-year-old Asian single female undergraduate senior Chief complaints - Persistent depression, anxiety/panic, and insomnia History of present illness - Recently self-discontinued lurasidone due to akathisia Past psychiatric history - Recurrent MDEs since age 12 - Paranoid ± referential delusions (when depressed) since age 1 - Recurrent delusional mixed episodes since age 17 - Hospitalized at age 21 for mixed episode with S/A by overdose - Prior pharmacotherapy SGAs (3 prior SGAs self-discontinued due to side effects) - Lurasidone, Aripiprazole -> akathisia; -> sedation - Never had Olanzapine, Ziprasidone, Risperidone, Clozapine Never had Mood stabilizers, Antidepressants, Benzodiazepines, ECT - No alcohol/substance use disorder - Current therapy No pharmacotherapy (self-discontinued lurasidone due to akathisia) No psychotherapy : Background (continued) Medical history Noncontributory (no obesity, diabetes, dyslipidemia) Weight 12 lbs; Height feet, inches; BMI 19. kg/m 2 Family history Sister (younger) with depression, ADHD, and panic disorder Maternal aunt hospitalized for bipolar disorder Paternal family history not available Social history College IT/philosophy senior (graduating in 9 months) Already had good job offer in NYC Lived in dorm on campus, with parents between terms
9 : Outpatient Visit Current depressive symptoms Sadness, anhedonia, insomnia ( hours) Feelings of guilt, psychomotor agitation, distractibility Passive suicidal ideation without intent, preparation, or plans Current psychotic symptoms Subthresold paranoid delusions ( severe anxiety) Current mood elevation symptoms Distractibility, psychomotor agitation Don t count towards DSM- mixed depression Current anxiety symptoms Panic attacks (2 in prior week, academic stress triggers) Generalized anxiety (daily) Current attitude towards medication Asking for treatment for depression, anxiety, and insomnia Question 1: Current Advisability of Antidepressants 1. Worth considering 2. Avoid Question 1: Current Advisability of Antidepressants Question 2: Current Advisability of Benzodiazepines Worth considering (probably not) Effective for unipolar MDD and anxiety Generally adequate somatic tolerability May exacerbate depression, destabilize mood Akathisia, suicidality, sexual dysfunction risks Avoid (probably) Inefficacy risk (likely also need antipsychotic) May exacerbate depression, destabilize mood Suicidality, sexual dysfunction, akathisia risks Effective for unipolar MDD and anxiety Generally adequate somatic tolerability 1. Worth considering 2. Avoid Question 2: Current Advisability of Benzodiazepines Worth considering (probably) Prominent panic/anxiety/insomnia/psychomotor agitation Generally adequate tolerability Limited sedation risk; can attenuate (rather than trigger) akathisia Limited utility of other agents Mood stabilizers have at best most modest anxiolytic effects Antidepressants might destabilize mood 3 SGAs already overly sedating/activating No personal/family history of alcohol/substance use disorder May ultimately prove necessary to attenuate akathisia Addiction potential (not extreme in this patient) Unlikely to relieve psychosis (unless actually severe anxiety) May exacerbate depression (?) Avoid (probably not) Addiction potential (not extreme in this patient) Might exacerbate depression (?) Follow-up Visits 2 and 3 Started weekly individual psychotherapy Lorazepam. mg twice daily Adequately tolerated Modestly attenuated anxiety/panic, insomnia, subthreshold psychosis No improvement in depression Lorazepam. mg each morning + 1 mg each bedtime Inadequately tolerated (sedation) No additional attenuation of anxiety/panic, insomnia, subthreshold psychosis Patient self-discontinued due to sedation and poorer academic productivity
10 Question 3: Current Advisability of Mood Stabilizers SGAs 1. Certain mood stabilizers 2. Certain SGAs Question 3: Current Advisability of Mood Stabilizers SGAs Certain mood stabilizers (probably not) Lithium, divalproex, carbamazepine, lamotrigine At best, only modest antidepressant, anxiolytic, and antipsychotic effects Lithium acne, tremor, weight gain Divalproex PCOS exacerbation risk Carbamazepine drug interactions Generally less sedation, akathisia, weight gain than SGAs Certain SGAs (probably) History of prominent psychotic symptoms Olanzapine + fluoxetine, quetiapine, lurasidone approved for bipolar depression Generally more side effects than mood stabilizers Already failed quetiapine, lurasidone, and aripiprazole Question : Choice of SGA 1. Olanzapine (with fluoxetine) 1 2. Ziprasidone 2,3 3. Risperidone. Clozapine 1 Tohen M, et al. Arch Gen Psychiatry. 23;(11): Lombardo I, et al. J Clin Psychopharmacol. 212;32(): Sachs GS, et al. J Clin Psychiatry. 211;72(1): Shelton RC, et al. J Clin Psychiatry. 2;(12): Suppes T, et al. Am J Psychiatry. 1999;1(8): Question : Choice of SGA Olanzapine with fluoxetine (probably) Established efficacy for bipolar depression/anxiety 1 Limited akathisia risk 2,3 Weight gain/metabolic > sedation/somnolence risks Ziprasidone (probably not) Inefficacy risk, ; akathisia risk Weight neutral Risperidone (probably not) Inefficacy risk; akathisia, other EPS, hyperprolactinemia risks Potent antipsychotic effect; as adjunct may help rapid cycling Clozapine (probably not) 7 Side effects risks (agranulosytosis/sedation/weight gain/metabolic) Inefficacy risk (very limited antidepressant benefit) May attenuate insomnia/anxiety; minimal akathisia risk 1 Tohen M, et al. Arch Gen Psychiatry. 23;(11): Lieberman JA, et al. N Engl J Med. 2;33(12): Gao K, et al. J Clin Psychopharmacol. 28;28(2): Lombardo I, et al. J Clin Psychopharmacol. 212;32():7-78. Sachs GS, et al. J Clin Psychiatry. 211;72(1): Shelton RC, et al. J Clin Psychiatry. 2;(12): Suppes T, et al. Am J Psychiatry. 1999;1(8): Unapproved SGAs in Bipolar Depression Efficacy intolerability concerns Olanzapine (monotherapy) 1,2 Inefficacy and intolerability concerns Risperidone 3, clozapine (no published placebocontrolled depression trials) Inefficacy concerns Aripiprazole, ziprasidone,7 Asenapine, iloperidone (no published controlled trials) ± Cariprazine (limited controlled data) 8 1 Tohen M, et al. Arch Gen Psychiatry. 23;(11): Tohen M, et al. Br J Psychiatry. 212;21(): Shelton RC, et al. J Clin Psychiatry. 2;(12): Suppes T, et al. Am J Psychiatry. 1999;1(8): Thase ME, et al. J Clin Psychopharmacol. 28;28(1):13-2. Lombardo I, et al. J Clin Psychopharmacol. 212;32(): Sachs GS, et al. J Clin Psychiatry. 211;72(1): Durgam S, et al. Am J Psychiatry. 21;173(3): Follow-up Visits and Olanzapine plus fluoxetine Titrated to Olanzapine 7. mg at bedtime Fluoxetine 2 mg each morning Good efficacy, with substantially attenuated Anxiety/panic and insomnia Depression Good tolerability No akathisia, minimal sedation Weight gain lbs at 12 weeks (BMI 19. -> 2.2 kg/m 2 ) Good academic function All A s last term
11 Conclusions Practical Take-Aways Candidates for beyond first-line interventions Inadequate efficacy, safety/tolerability, feasibility Urgent efficacy need Clinical circumstances important Accurate diagnoses (primary secondary) Illness phase (acute mania/depression, maintenance) Illness characteristics (rapid cycling, comorbidities, med Hx) Efficacy need (urgent non-urgent care) Primary priority (efficacy tolerability) Beyond first-line intervention options include Switching (no efficacy and/or inadequate tolerability) Augmenting (partial efficacy and adequate tolerability) Adjunctive psychosocial treatments Publishing, Inc.; 21. Treatment resistance risks Bipolar depression, mixed episodes Comorbid disorders, rapid cycling Treatment options (commonly combination therapy) SGAs (± mood stabilizers, antidepressants, anxiolytics) Caution with antidepressants (± SGA/MS counter-balance) Novel adjuncts occasionally beneficial Thyroid, pramipexole, topiramate, nutriceuticals, sleep dep, light Rx Adjunctive psychosocial interventions Try to move from symptomatic to functional recovery Publishing, Inc.; 21.
Treatment of Bipolar disorder
8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence
More informationSolving Clinical Challenges in Bipolar Disorder
Overview Bipolar Disorder Solving Clinical Challenges Solving Clinical Challenges in Bipolar Disorder Terence A. Ketter, MD Professor Emeritus Department of Psychiatry and Behavioral Sciences Stanford
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationManagement of Bipolar Depression
Management of Bipolar Depression Haresh M. Tharwani, M.D. Associate Clinical Professor Medical Director-DRH & Duke Psychiatry Specialty Clinic of Cary, N.C. Bipolar Disorders (Manic-Depressive illness)
More informationPsychiatry Clinical Reviews Treating Bipolar Depression
Mayo School of Continuous Professional Development Psychiatry Clinical Reviews Treating Bipolar Depression Mark A. Frye, MD October 6-8, 2016 Intercontinental Chicago Magnificent Mile Chicago, IL 2015
More informationBipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationFixing the Mix-Up Over Mixed Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Fixing the Mix-Up Over Mixed Depression Diagnosing and Treating DSM-5 Defined Mixed Features in Mood Disorders Learning Objectives
More informationBIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationIndex. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers
Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) a-adrenergic blockers for PTSD, 798 b-adrenergic blockers for PTSD, 798 Adrenergic
More informationEffectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials
International Journal of Neuropsychopharmacology (2011), 14, 1029 1049. f CINP 2011 doi:10.1017/s1461145711000885 Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder:
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationA systematic review of the evidence on the treatment of rapid cycling bipolar disorder
Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid
More informationPharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC
Pharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC Professor of Psychiatry and Pharmacology University of Toronto Head, Mood Disorders Psychopharmacology Unit University Health Network Toronto,
More informationPsychiatry Clinical Reviews Mania Matters
Mayo School of Continuous Professional Development Psychiatry Clinical Reviews Mania Matters Mark A. Frye, MD October 6-8, 2016 Intercontinental Chicago Magnificent Mile Chicago, IL Disclosures- Mark A.
More informationBipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression
Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationTreatment Options for Bipolar Disorder Contents
Keeping Your Balance Treatment Options for Bipolar Disorder Contents Medication Treatment for Bipolar Disorder 2 Page Medication Record 5 Psychosocial Treatments for Bipolar Disorder 6 Module Summary 8
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationComprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr, MD, MSc 1 David J. Bond, MD, PhD 2,*
Current Treatment Options in Psychiatry (2014) 1:263 277 DOI 10.1007/s40501-014-0017-2 Mood Disorders (AH Young, Section Editor) Comprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr,
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationManaging Bipolar Depression and Mixed Episodes
Managing Bipolar Depression and Mixed Episodes Outline Diagnosing bipolar disorder with DSM-5 Treating mixed features of bipolar disorder Improving health outcomes in bipolar depression Role of psychosocial
More informationIt's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum
It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum Session 4022: American Psychiatric Nurses Association National Conference, Louisville, KY Andrew Penn, RN, MS, NP, CNS Psychiatric
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationDSM-5 Criteria: Bipolar Disorders
DSM-5 Criteria: Bipolar Disorders Box 1. Bipolar I Disorder: For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic episode. The manic episode may have been preceded
More informationDepression in Late Life
Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression
More informationImproving Diagnosis and Symptoms in Patients With Bipolar Depression: Contemporary Strategies Discussion 1
Discussion 1 The following is a transcript from a Web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational
More informationBipolar Disorder A Focus on Depression
clinical practice Bipolar Disorder A Focus on Depression Mark A. Frye, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationSOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES
SOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES Learning Objectives Impart the importance of screening for the presence of mixed features and family
More informationObjectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System
Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationTreatment-resistant depression in primary care
Treatment-resistant depression in primary care Interprofessional CME, October 2017 Brian J. Mickey, MD, PhD Associate Professor School of Medicine Department of Psychiatry Disclosures Speakers bureau:
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationDepression in adults: treatment and management
1 2 3 4 Depression in adults: treatment and management 5 6 7 8 Appendix V3: recommendations that have been deleted of changed from 2009 guideline Depression in adults: Appendix V3 1 of 22 1 Recommendations
More informationDSM-5 Criteria: Major Depressive Disorder
DSM-5 Criteria: Major Depressive Disorder Box 3. Major Depressive Episode: DSM-5 Diagnosis: Major Depressive Disorder Five (or more) of the following symptoms have been present during the same 2-week period
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationTreatment strategies in major depression What to use when?
Treatment strategies in major depression What to use when? Michael Bauer, MD, PhD Professor and Chair of Psychiatry University Hospital Carl Gustav Carus Technische Universität Dresden Germany First-line
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationTreatment of Anxiety and Mood Disorders. John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY
Treatment of Anxiety and Mood Disorders John T. Walkup, MD Division of Child and Adolescent Psychiatry Weill Cornell Medical College New York, NY Disclosure: John T. Walkup, MD Consultant Advisory Board
More informationPediatrics Grand Rounds 5 March University of Texas Health Science Center at San Antonio I-1
Diagnosis and Treatment of Depression in Children and Adolescents Steven R. Pliszka, M.D. Professor and Vice Chair Chief, Division of Child and Adolescent Psychiatry Department of Psychiatry The Disclosures
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationBipolar disorder, sometimes called manicdepressive
XXASIN_2_4_p151_157 10/25/04 3:45 PM Page 151 ROLE OF ANTIPSYCHOTIC MEDICATIONS IN TREATING BIPOLAR DISORDER * Mary Jane Strong, APRN, MS, CS ABSTRACT Although no cure exists for bipolar disorder, treatment
More informationComparison of the Usefulness of Lithium and Valproate
Review Article CNPT4(2013) 1-5 Comparison of the Usefulness of Lithium and Valproate, M.D., Ph.D. Department of Neuropsychiatry, Oita University Faculty of Medicine ABSTRACT This review shows that lithium
More informationWorking with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers
Working with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers Tuesday, February 23, 2016 2pm Eastern Delbert Robinson, M.D. Professor of Psychiatry and Molecular Medicine
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationfor anxious and avoidant behaviors.
Summary of the Literature on the Treatment of Anxiety Disorders in Children and Adolescents Sucheta D. Connolly, M.D.* Non-OCD anxiety disorders in youth are common and disabling, with 12-month prevalence
More informationD I A G N O S I S ADD/ADHD. Conduct Disorder. Oppositional. Oppositional Defiant Disorder. Defiant. Anxiety Disorder. Adjustment.
Dr. Crismon has no potential conflicts of interest to disclose with regard to this presentation. M. Lynn Crismon, Pharm.D., FCCP, BCPP Dean James T. Doluisio Regents Chair & Behrens Centennial Professor
More informationBIPOLAR DISORDERS UPDATE. Anthony Archer, DO
BIPOLAR DISORDERS UPDATE Anthony Archer, DO OBJECTIVES Review the major developments and trends in diagnosis and management of bipolar disorders. Discuss and promote the role of the primary care physician
More informationAny news of innovative treatment options in schizoaffective disorder?
Any news of innovative treatment options in schizoaffective disorder? Andrea Murru, MD, PhD Lisbon, 26th of April 2015 Centro de Investigación Biomédica En Red de Salud Mental Conflitti di Interesse Name
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationPractical Psychopharmacology for More Complex Mental Health Presentations
MINISTRY OF CHILDREN AND YOUTH SERVICES Practical Psychopharmacology for More Complex Mental Health Presentations Part 2: Antipsychotics & Mood Stabilizers Dr. Ajit Ninan & Joel Lamoure 1 : Who are we?
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationDISEASES AND DISORDERS
DISEASES AND DISORDERS 13. The mood (affective) disorders 99 14. The psychotic disorders: schizophrenia 105 15. The anxiety and somatoform disorders 111 16. Dementia and delirium 117 17. Alcohol and substance-related
More informationAntidepressant Utilization in Bipolar Disorder: What Is the Evidence?
Antidepressant Utilization in Bipolar Disorder: What Is the Evidence? 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC March 2018 MRC2.CORP.D.00336 Today s
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
BadgerCare Plus Preferred Practice Guidelines Bipolar Disorder in Children and Adolescents These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice
More informationLong-term Treatment in Bipolar Disorder: Fall 2015 Update
Long-term Treatment in Bipolar Disorder: Fall 2015 Update Roy H. Perlis, MD MSc Center for Experimental Drugs and Diagnostics Massachusetts General Hospital Harvard Medical School rperlis@partners.org
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationBipolar treatment update
Bipolar treatment update Evidence is driving change Texas Medication Algorithm Project will weigh data on atypical antipsychotics in mania and on continuing antidepressants after bipolar depression remits.
More informationClozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders
Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationPORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016
Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the
More informationBipolar Disorder Demystified. Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry
Bipolar Disorder Demystified Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry Underdiagnoses of Depression In Primary Care 2005 Study of 650 primary care patients on antidepressants
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationEarly Intervention in Bipolar Disorder Depends on Early Identification: Strategies for Optimizing Positive Outcomes
Early Intervention in Bipolar Disorder Depends on Early Identification: Strategies for Optimizing Positive Outcomes Ellen Frank, PhD Distinguished Professor of Psychiatry, University of Pittsburgh School
More informationPregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)
Pregnancy General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition) In all women of child bearing potential Always discuss the possibility of pregnancy; half of all pregnancies are unplanned
More informationBipolar disorders: treatment options and patient satisfaction
REVIEW Bipolar disorders: treatment options and patient satisfaction Charles Bowden Vivek Singh Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX,
More informationEffective Health Care Program
Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the
More informationComprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula
Comprehensive Quick Reference Handout on Pediatric Bipolar Disorder By Jessica Tomasula Official Name Bipolar Disorder; also referred to as Manic Depression Definitions (DSM-IV-TR, 2000) Bipolar I Disorder
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationREXULTI (brexpiprazole) oral tablet
REXULTI (brexpiprazole) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationFamily Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University
APPROACH TO DEPRESSION IN PRIMARY CARE Family Medicine Forum November 10, 2017 Montreal., Quebec. Jon Davine, CCFP, FRCP(C) Associate Professor, McMaster University DISCLOSURE Speaker/Presenter Disclosure
More information